| Literature DB >> 29143800 |
Paolo Bazzigaluppi1,2, Azin Ebrahim Amini3,4, Iliya Weisspapir5, Bojana Stefanovic6, Peter L Carlen7,8.
Abstract
Epilepsy afflicts up to 1.6% of the population and the mechanisms underlying the appearance of seizures are still not understood. In past years, many efforts have been spent trying to understand the mechanisms underlying the excessive and synchronous firing of neurons. Traditionally, attention was pointed towards synaptic (dys)function and extracellular ionic species (dys)regulation. Recently, novel clinical and preclinical studies explored the role of brain metabolism (i.e., glucose utilization) of seizures pathophysiology revealing (in most cases) reduced metabolism in the inter-ictal period and increased metabolism in the seconds preceding and during the appearance of seizures. In the present review, we summarize the clinical and preclinical observations showing metabolic dysregulation during epileptogenesis, seizure initiation, and termination, and in the inter-ictal period. Recent preclinical studies have shown that 2-Deoxyglucose (2-DG, a glycolysis blocker) is a novel therapeutic approach to reduce seizures. Furthermore, we present initial evidence for the effectiveness of 2-DG in arresting 4-Aminopyridine induced neocortical seizures in vivo in the mouse.Entities:
Keywords: 2 deoxyglucose; beta hydroxybutyrate; epilepsy; metabolism; seizures
Mesh:
Year: 2017 PMID: 29143800 PMCID: PMC5713239 DOI: 10.3390/ijms18112269
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Schematic representation of the metabolic pathways followed by glucose and ketones.
Figure 2(A) Local Field potential recordings (orange) and extracellular potassium concentration (in purple); approximately 3 min following 4-Aminopyridine (4-AP) administration (arrow) recurrent seizures appear. Fifteen minutes after the first seizure, 2-deoxy-d-glucose (2-DG) is injected intraperitoneally. In the minutes to hours following 2-DG administration, seizures were reduced in duration and power, accompanied by a decrease in Ke. In (Bi) representative segment of field potential recording during baseline in orange and (below) its wavelet transform, (Bii) representative field potential recording during a 4-AP seizure in orange and (below) its wavelet transform, (Biii) representative field potential recording of a seizure in orange ~35 min following 2-DG administration and (below) its wavelet transform; (Ci) the duration of every seizure is plotted 4-AP seizures (n = 8) have an average duration of 85.1 ± 25.4 s. Following 2-DG, seizure duration is reduced. (Cii) uring 4-AP seizures (n = 8), the average power increase from the mean baseline power was 48.2 ± 6.2% in theta (p < 0.005), 19.9 ± 8.8% in alpha (p < 1 × 10−5), 104.5 ± 12.1% in beta (p < 1 × 10−5), 128.1 ± 5.9% in low gamma (p < 1 × 10−5) and 179.5 ± 9.2% in high gamma (p < 1 × 10−5). Thirty minutes following 2-DG administration, the average power of eight seizures decreased of 73.1 ± 10.1% in theta (p = 0.002), 90.6 ± 21.3% in alpha (p = 0.001), 108.8 ± 14.2% in beta (p < 1 × 10−5), 100.3 ± 31.2% in low gamma (p < 1 × 10−5) and 106.7 ± 21.5% in high gamma (p < 1 × 10−5) from the average power during 4-AP.